Custom CRISPR Targeted Lentiviral sgRNA Library
Studying a large family of genes, or a complex pathway? Now you can knock out, activate, or repress up to 100 target genes of your choice with a single Custom CRISPR Targeted sgRNA Lentivector/Lentivirus pool. Our sgRNA library provides you with up to 300 sgRNAs and includes deliverables of both pooled sgRNA lentiviral vector and pooled lentivirus. Inquire with us below to get started on your custom CRISPR project.
Applications:
- Gene Activation using dCas9-VPR
- Gene Repression using dCas9-KRAB
- Gene Knockout using spCas9
Service Details
| Service | Vector | Deliverable 1 | Deliverable 2 | Cat. No. | Lead Time | Price |
|---|---|---|---|---|---|---|
| Custom CRISPR Targeted Lentiviral sgRNA Library | pLenti-U6-sgRNA-PGK-Neo | 100 µg of pooled lentiviral vector | 1 ml of 107 IU/ml pooled lentivirus | C209 | 8-12 weeks | $9,950.00 |
Additional Info
Additional Resources
Documents
FAQs
| Is Cas9 included in the package? |
| How many vials of Cas9 Nuclease will be required? |
|
The sgRNA plasmids will be supplied as a pool of lentiviral vectors, and a single vial of at least 1 mL of packaged virus will be supplied. Only a single tube of Cas9 Nuclease Lentiviral Vector (Cat. No. K002) is required as it can be amplified by transforming into E. coli and isolating the DNA. If Cas9 Nuclease Lentivirus (Cat. No. K003) is ordered, the amount required will depend on how many different samples the end user is interested in infecting. If you are only working with a few cell ines, then 1 vial may be sufficient to infect the cell to generate stable cell lines expressing Cas9 Nuclease for use with the pool. If you are working with more cell lines, then more than 1 vial may be required.
|
| What species is this service valid for? |
|
Human, mouse or rat. For other species, please inquire.
|
Citations
| 01 | Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371 |
| 02 | Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338 |
| 03 | Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359 |